(3R)-1-(3,5-Dichloro-pyridin-2-yl)-3-methyl-piperazine → 4-bromo-2-[(2R)-4-(3,5-dichloro-pyridin-2-yl)-2-methyl-piperazin-1-yl]-6-trifluoromethyl-1H-benzoimidazole
反応式
[Cl:1][C:2]1[C:3]([N:9]2[CH2:14][CH2:13][NH:12][C@H:11]([CH3:15])[CH2:10]2)=[N:4][CH:5]=[C:6]([Cl:8])[CH:7]=1.[Br:16][C:17]1[C:22]2[NH:23][C:24](Cl)=[N:25][C:21]=2[CH:20]=[C:19]([C:27]([F:30])([F:29])[F:28])[CH:18]=1>O1CCOCC1>[Br:16][C:17]1[C:22]2[N:23]=[C:24]([N:12]3[CH2:13][CH2:14][N:9]([C:3]4[C:2]([Cl:1])=[CH:7][C:6]([Cl:8])=[CH:5][N:4]=4)[CH2:10][C@H:11]3[CH3:15])[NH:25][C:21]=2[CH:20]=[C:19]([C:27]([F:30])([F:29])[F:28])[CH:18]=1参加物
4
実験手順
A mixture of the piperazine from step (a) above (148 mg, 0.6 mmol) and 7-bromo-2-chloro-5-trifluoromethyl-1H-benzoimidazole (150 mg, 0.5 mmmol, Example 6b) in dioxane (2 mL) reacted under the conditions of Example 3c to give the title compound. Mp: 135-137° C. MS (ESI, pos. ion) m/z: 510 (M+1)